Milltrust Ventures invests in Oncoshot, a first-class healthcare technology platform


SINGAPORE, March 22, 2022 /PRNewswire/ – Oncoshot has announced that it will welcome Dr. Bernard Ng, chief scientific officer of Milltrust Ventures, to its advisory board this month. This is a first step, as the specialist investment organization funds the fast-growing health technology company founded in Singapore.

Milltrust Ventures is a subsidiary of Milltrust International Group, a specialist investment organization co-headquartered in the asset management centers of London and Singapore. It invests in high-potential science and technology-driven start-ups that can have a positive impact on individual health and healthcare systems. Milltrust Ventures filters and identifies start-ups from the UK and European ecosystems, and Asiaspecifically Singaporewhich is home to a thriving start-up ecosystem with strong backing and backing from good policies and government aid.

Oncoshot is a health information exchange platform that leverages its proprietary clinical trial-matching artificial intelligence (AI) technology to address inefficiencies in cancer clinical trials. The platform serves as a bridge between leading regional healthcare institutions and contract research organizations (CROs) and global biotech and pharmaceutical companies to facilitate data-driven cancer clinical trials while accelerating enrollment in those who are actively recruiting.

The Oncoshot platform generates relevant real-time, hospital-approved leads for trials in minutes, by sorting over 100,000 anonymized patient profiles spanning its three initial markets. With the traditional approach, this process can take weeks to months. Reducing the time spent in registration steps can save clinical trial stakeholders tens of thousands of dollars a day.

“Milltrust Ventures is proud to be an investor for Oncoshot. We see the value this health information platform can bring to the field of cancer clinical trials globally and the potential for Oncoshot to drive this system,” said Dr. starting with enabling patients to link to near real-time and later-stage trials, generating insights from the wealth of data for real-world evidence to help how we fight cancer at a population level and of the individual.

Prior to his role at Milltrust Ventures, Dr. Ng was Vice President and Head of Global Medical and Clinical Affairs at Bayer Consumer Healthcare. As a respected medical and clinical affairs industry veteran, he will bring 23 years of global, regional and local experience to Oncoshot.

He will join Curie Oncology Senior Consultant and Medical Oncologist Dr. John Chia; CEO of Ekomed Technologies John McEndry; and Supra Oncology Founder and former CEO of Pfizer Srini Srinivasan guiding Oncoshot as it develops as a first-class fair health information exchange platform for cancer clinical trials.

This strategic investment from Milltrust Ventures enables the investment organization to participate in future Oncoshot funding rounds. In return, it will support Oncoshot with early-to-market engagement among healthcare systems and industry partners in APAC. Milltrust Ventures will also assist Oncoshot in its expansion into Australia and Indiawhere the latter has already established partnerships between leading cancer institutes, with early commercialization by leading pharmaceutical companies and CROs, as he did in his home country.

About Oncoshot

Oncoshot was founded in 2018 by Dr. Huren Sivaraj, a medical oncologist, and Ruslan Enikeev, a data science engineer and creator of Map of the Internet, a popular web traffic data visualization tool. Oncoshot’s mission is to help oncologists more effectively identify cancer clinical trials for patients and their caregivers by supporting hospitals and research partners. His current focus is to leverage technology to address inefficiencies in cancer clinical trials. Oncoshot has expanded to Australia and India since its creation in Singaporean act that highlights its applicability and success.

SOURCEOncoshot Pte Ltd

Previous Industry group pushes back smart home standard
Next Terra e Mare opens in Jersey City, and more restaurant news